Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 02/03/2026 at 07:00, 5 months 13 days ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment
BRIEF

published on 01/07/2026 at 07:05, 6 months 9 days ago

Début d'un essai clinique pour l'événamide au Japon

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Essai De Phase III EA Pharma
BRIEF

published on 01/07/2026 at 07:05, 6 months 9 days ago

Clinical Trial for Evenamide in Japan Commences

Phase III Trial Newron Pharmaceuticals Evenamide Schizophrenia Treatment EA Pharma
PRESS RELEASE

published on 01/07/2026 at 07:00, 6 months 9 days ago

Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai

Schizophrenia Newron Pharmaceuticals Evenamide Phase III EA Pharma
BRIEF

published on 01/06/2026 at 07:05, 6 months 10 days ago

Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Patent Schizophrenia Newron Pharmaceuticals Evenamide Glutamate Modulation
BRIEF

published on 01/06/2026 at 07:05, 6 months 10 days ago

Newron Pharmaceuticals renforce son portefeuille de propriété intellectuelle pour Evenamide

Schizophrénie Brevet Newron Pharmaceuticals Evenamide Modulation Du Glutamate
PRESS RELEASE

published on 01/06/2026 at 07:00, 6 months 10 days ago

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Newron Pharmaceuticals obtains new EU Composition of Matter Patent EP4615820 for Evenamide, extending exclusivity into 2044

Patent Intellectual Property Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 12/08/2025 at 07:05, 7 months 8 days ago

Newron lance une étude de phase III aux États-Unis sur l'événamide pour la schizophrénie

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Étude De Phase III
BRIEF

published on 12/08/2025 at 07:05, 7 months 8 days ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 7 months 8 days ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2

Published on 07/17/2026 at 01:00, 3 hours 38 minutes ago

RJK Explorations Ltd. Announces Closing of Private Placement for Gross Proceeds of $310,000
Published on 07/17/2026 at 00:00, 4 hours 38 minutes ago

LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
Published on 07/16/2026 at 16:21, 12 hours 17 minutes ago

First Canadian Graphite Completes Phase I Exploration on Zone 13 Discovery and Expands Lands Package
Published on 07/16/2026 at 15:30, 13 hours 8 minutes ago

Caldwell Announces Leadership Appointments for Industrial Practice and Caldwell Analytics
Published on 07/16/2026 at 15:30, 13 hours 8 minutes ago

Resilient Energy Inc. Advances Commercial Rollout; Operations Enter Final Stage Ahead of Revenue Generation

View all ACCESSWIRE

Published on 07/17/2026 at 02:10, 2 hours 28 minutes ago

VARON Highlights Summer Wellness with Portable Oxygen Solutions for Active Lifestyles
Published on 07/16/2026 at 23:10, 5 hours 28 minutes ago

EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
Published on 07/16/2026 at 21:16, 7 hours 22 minutes ago

Hertz Energy Advances Its Lake George Antimony-Tungsten Project and Summarizes Lithium Project
Published on 07/16/2026 at 20:59, 7 hours 39 minutes ago

EQS-Adhoc: SMA publishes preliminary results for the second quarter of 2026 and raises full-year 2026 guidance
Published on 07/16/2026 at 20:39, 7 hours 59 minutes ago

AUTODOC successfully optimises capital structure

View all EQS

Published on 07/16/2026 at 20:27, 8 hours 11 minutes ago

BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Published on 07/16/2026 at 18:08, 10 hours 30 minutes ago

Aéroports de Paris S.A - June and half-year 2026 traffic figures
Published on 07/16/2026 at 18:08, 10 hours 30 minutes ago

Aéroports de Paris S.A - Trafic du mois de juin et du 1er semestre 2026
Published on 07/16/2026 at 18:00, 10 hours 38 minutes ago

i2S Chiffre d'affaires S1 2026
Published on 07/16/2026 at 17:45, 10 hours 53 minutes ago

H1 2026 revenue: €6.1m (+14%)

View all LES ECHOS COMFI WIRE

News